Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 14/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10051880 | 0.83 | AHCY (0.74) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 | |
| SCHEMBL26382114 | 0.83 | AHCY (0.74) | AHCYADORA2A | |
| SCHEMBL12281124 | 0.82 | AHCY (1.00) | AHCYADORA2A | |
| SCHEMBL26382111 | 0.82 | AHCY (1.00) | AHCYADORA2A | |
| Hydrochloric Acid SCHEMBL1935723 | 0.81 | AHCY (0.97) | AHCYADORA2A | |
| SCHEMBL864418 | 0.80 | AHCY (0.81) | AHCY | |
| SCHEMBL12280561 | 0.80 | AHCY (0.81) | AHCY | |
| Neoplanocin A SCHEMBL10576831 | 0.80 | AHCY (1.00) | AHCYADORA2AADORA2B | |
| Neoplanocin A SCHEMBL10469277 | 0.80 | AHCY (1.00) | AHCYADORA2AADORA2B | |
| Neoplanocin A SCHEMBL863873 | 0.80 | AHCY (1.00) | AHCYADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522352-B1 | Methods for stem cells modulation | AGENCY SCIENCE TECH & RES (SG) | 2017-01-11 | — | — | EP | disclosed |
| EP-1993553-B1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY SCIENCE TECH & RES (SG) | 2013-05-08 | — | — | EP | disclosed |
| EP-2522352-A1 | Methods for cancer therapy and stem cell modulation | Agency for Science, Technology and Research (SG) | 2012-11-14 | — | — | EP | disclosed |
| US-8211869-B2 | Methods for cancer therapy and stem cell modulation | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-07-03 | — | — | US | disclosed |
| US-20120077841-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-03-29 | — | — | US | disclosed |
| US-8058258-B2 | Methods for cancer therapy and stem cell modulation | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-11-15 | — | — | US | disclosed |
| US-20100075915-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-03-25 | — | — | US | disclosed |
| EP-1993553-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | Agency for Science, Technology and Research (SG) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007100304-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075915-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | MCL1, BCOR, BCL2 | AHCY 2998/4885HIF1A 204/4885TMEM97 1393/4885 |
| US-20120077841-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | HCCS, MCL1, AHR | AHCY 1749/4885HIF1A 99/4885TMEM97 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.